Cardiac Amyloidosis: No Longer Rare and Untreatable!

Mayo Clinic Cardiovascular CME

Cardiac Amyloidosis: No Longer Rare and Untreatable!

Guest: Omar F. Abou Ezzeddine, M.D., M.S.

Hosts: Malcolm R. Bell, M.D.

Transthyretin amyloid cardiomyopathy (ATTR-CM), once considered rare, is more prevalent than previously thought. Diagnosing ATTR-CM is particularly important because there are now highly effective, specific therapies for ATTR-CM. In this podcast, we will provide a contemporary review of the diagnostic and therapeutic approach to patients with ATTR-CM in the current era.

Topics Discussed:

• When to suspect the disease & who to screen for ATTR-CM?
• How to diagnose and prognosticate ATTR-CM in the current era?
• Provide an overview of current and emerging therapies for managing ATTR-CM.

Connect with Mayo Clinic's Cardiovascular Continuing Medical Education online at https://cveducation.mayo.edu or on Twitter @MayoClinicCV and @MayoCVservices.

LinkedIn: Mayo Clinic Cardiovascular Services

Cardiovascular Education App:
The Mayo Clinic Cardiovascular CME App is an innovative educational platform that features cardiology-focused continuing medical education wherever and whenever you need it. Use this app to access other free content and browse upcoming courses. Download it for free in Apple or Google stores today!

No CME credit offered for this episode.

Podcast episode transcript found here.